Lentinan dose dependence between immunoprophylaxis and promotion of the murine liver cancer

// Ying Wang 1, 4 , Xue Han 2 , Yan Dong Li 3 , Yabing Wang 2 , Shi Yang Zhao 2 , Dong Jie Zhang 1 and Yu Lu 5 1 College of Food, Heilongjiang Bayi Agricultural University, Daqing 163319, PR China 2 College of Biological Science and Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, PR China 3 Hebei Institute of Veterinary Drugs Control, Shijiazhuang 050000, PR China 4 National Coarse Cereals Engineering Research Center, Daqing 163319, PR China 5 Huabei Petroleum Administration Bureau, Huasheng Integrated Service, Tianjin 300000, PR China Correspondence to: Xue Han, email: hanxue_h@163.com Keywords: lentinan; dose dependence; liver cancer; immunoprophylaxis; promotion Received: March 12, 2017 Accepted: April 21, 2017 Published: August 01, 2017 ABSTRACT Lentinan could exhibit significant biological activity favorable for human health and disease control such as the recovery of patients with liver cancer. In order to investigate the effect of lentinan dose dependence between immunoprophylaxis and promotion of cancer cell proliferation of the murine liver cancer, different concentrations of lentinan were prepared for the test in vitro (MTT assay) and in vivo (cumulative survival assay, spleen lymphocyte proliferation tests and peritoneal macrophage phagocytosis assays). New emerging proteins of the H22 cell incubated with lentinan was demonstrated by MS analysis and protein database searching. Lentinan was non-toxic for HL7702 cells but inhibited H22 cells proliferation obviously in a dose-dependent manner. In vivo , the proliferation of H22 hepatocarcinoma cells was inhibited by lentinan 0.4mg/kg body weight (L2, survival rate, 20%, P